Eddie currently heads life sciences investing at Pear VC, a venture firm in Menlo Park, CA, that specializes in seed-stage investments. Before joining Pear VC, Eddie led corporate development at Senti Biosciences, a company that leverages synthetic biology for next-generation cell and gene therapies, from its seed stage until just before its public financing. Eddie drove partnering collaborations with Spark/Roche in gene therapy and BlueRock/Bayer in regenerative medicine. Previously, Eddie worked at a drug delivery company spun out of MIT as a scientist in formulation and process scale-up for two ocular clinical drug candidates that are now FDA-approved products. He holds a PhD in Biological Engineering from MIT, where he pursued research on non-viral gene therapies, as well as an MBA from Stanford University’s Graduate School of Business.
